Company intelligence / Profile preview

LETI Pharma

Ownership: Private
Employees: ~750
Development stage: Commercial

Overview

The company has commercial products in immunology, allergy, dermatology, and animal health. They have a vaccine against canine Leishmaniosis called LetiFend®.

Therapeutic areas: ImmunologyDermatologyInfectious Diseases
Modalities: Allergen extractsImmunotherapyVaccines
Industry: Biotech

Drug pipeline

39 assets

Depigoid

38 more assets in the full pipeline.

Request access →

Partnerships

MSD Animal Health (for distribution of LetiFend® vaccine in France, Italy, Greece, and soon Great Britain)partnerships with universities and research centers

Beyond the preview

Go deeper on LETI Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LETI Pharma.

Explore the full profile